Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel

Philipp Nuhn, Ajay M. Vaghasia, Jatinder Goyal, Xian C. Zhou, Michael A Carducci, Mario Eisenberger, Emmanuel Antonarakis

Research output: Contribution to journalArticle

Abstract

Objective To determine whether the pretreatment neutrophil-to-lymphocyte ratio (NLR), a measure of systemic inflammatory response, is associated with overall survival (OS) in men receiving chemotherapy with docetaxel for metastatic castration-resistant prostate cancer (mCRPC).

Patients and Methods Records from 238 consecutive patients who were treated with first-line docetaxel-containing chemotherapy for mCRPC at a single high-volume centre from 1998 to 2010 (and who had adequate information to enable calculation of NLR) were reviewed. Univariable and multivariable Cox regression models were used to predict OS after chemotherapy initiation.

Results In univariable analyses, the NLR as a discrete variable (optimal threshold 3.0) was significantly associated with OS (P = 0.001). In multivariable analyses, a lower NLR (≤3.0) was associated with lower risk of all-cause mortality (P = 0.002). In Kaplan-Meier analysis, the median OS was higher (18.3 vs 14.4 months) in patients that did not have an elevated NLR than in those with an elevated NLR (log-rank; P <0.001).

Conclusions Men who were treated with first-line docetaxel for mCRPC who had a low pretreatment NLR (≤3.0) had significantly longer OS. NLR may be a potentially useful clinical marker of systemic inflammatory response in predicting OS in men with mCRPC who receive docetaxel and may be helpful to stratify patients for clinical trials. These findings derived from a retrospective analysis need to be validated in larger populations in prospective studies, and in the context of different therapies.

Original languageEnglish (US)
Pages (from-to)E11-E17
JournalBJU International
Volume114
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Neutrophils
Lymphocytes
Survival
Drug Therapy
Kaplan-Meier Estimate
Proportional Hazards Models

Keywords

  • chemotherapy
  • docetaxel
  • metastatic castration-resistant prostate cancer
  • neutrophil-to-lymphocyte ratio
  • overall survival
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

@article{12f368aa216149ec9a9ea7b1c5056554,
title = "Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel",
abstract = "Objective To determine whether the pretreatment neutrophil-to-lymphocyte ratio (NLR), a measure of systemic inflammatory response, is associated with overall survival (OS) in men receiving chemotherapy with docetaxel for metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods Records from 238 consecutive patients who were treated with first-line docetaxel-containing chemotherapy for mCRPC at a single high-volume centre from 1998 to 2010 (and who had adequate information to enable calculation of NLR) were reviewed. Univariable and multivariable Cox regression models were used to predict OS after chemotherapy initiation.Results In univariable analyses, the NLR as a discrete variable (optimal threshold 3.0) was significantly associated with OS (P = 0.001). In multivariable analyses, a lower NLR (≤3.0) was associated with lower risk of all-cause mortality (P = 0.002). In Kaplan-Meier analysis, the median OS was higher (18.3 vs 14.4 months) in patients that did not have an elevated NLR than in those with an elevated NLR (log-rank; P <0.001).Conclusions Men who were treated with first-line docetaxel for mCRPC who had a low pretreatment NLR (≤3.0) had significantly longer OS. NLR may be a potentially useful clinical marker of systemic inflammatory response in predicting OS in men with mCRPC who receive docetaxel and may be helpful to stratify patients for clinical trials. These findings derived from a retrospective analysis need to be validated in larger populations in prospective studies, and in the context of different therapies.",
keywords = "chemotherapy, docetaxel, metastatic castration-resistant prostate cancer, neutrophil-to-lymphocyte ratio, overall survival, prostate cancer",
author = "Philipp Nuhn and Vaghasia, {Ajay M.} and Jatinder Goyal and Zhou, {Xian C.} and Carducci, {Michael A} and Mario Eisenberger and Emmanuel Antonarakis",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/bju.12531",
language = "English (US)",
volume = "114",
pages = "E11--E17",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel

AU - Nuhn, Philipp

AU - Vaghasia, Ajay M.

AU - Goyal, Jatinder

AU - Zhou, Xian C.

AU - Carducci, Michael A

AU - Eisenberger, Mario

AU - Antonarakis, Emmanuel

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective To determine whether the pretreatment neutrophil-to-lymphocyte ratio (NLR), a measure of systemic inflammatory response, is associated with overall survival (OS) in men receiving chemotherapy with docetaxel for metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods Records from 238 consecutive patients who were treated with first-line docetaxel-containing chemotherapy for mCRPC at a single high-volume centre from 1998 to 2010 (and who had adequate information to enable calculation of NLR) were reviewed. Univariable and multivariable Cox regression models were used to predict OS after chemotherapy initiation.Results In univariable analyses, the NLR as a discrete variable (optimal threshold 3.0) was significantly associated with OS (P = 0.001). In multivariable analyses, a lower NLR (≤3.0) was associated with lower risk of all-cause mortality (P = 0.002). In Kaplan-Meier analysis, the median OS was higher (18.3 vs 14.4 months) in patients that did not have an elevated NLR than in those with an elevated NLR (log-rank; P <0.001).Conclusions Men who were treated with first-line docetaxel for mCRPC who had a low pretreatment NLR (≤3.0) had significantly longer OS. NLR may be a potentially useful clinical marker of systemic inflammatory response in predicting OS in men with mCRPC who receive docetaxel and may be helpful to stratify patients for clinical trials. These findings derived from a retrospective analysis need to be validated in larger populations in prospective studies, and in the context of different therapies.

AB - Objective To determine whether the pretreatment neutrophil-to-lymphocyte ratio (NLR), a measure of systemic inflammatory response, is associated with overall survival (OS) in men receiving chemotherapy with docetaxel for metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods Records from 238 consecutive patients who were treated with first-line docetaxel-containing chemotherapy for mCRPC at a single high-volume centre from 1998 to 2010 (and who had adequate information to enable calculation of NLR) were reviewed. Univariable and multivariable Cox regression models were used to predict OS after chemotherapy initiation.Results In univariable analyses, the NLR as a discrete variable (optimal threshold 3.0) was significantly associated with OS (P = 0.001). In multivariable analyses, a lower NLR (≤3.0) was associated with lower risk of all-cause mortality (P = 0.002). In Kaplan-Meier analysis, the median OS was higher (18.3 vs 14.4 months) in patients that did not have an elevated NLR than in those with an elevated NLR (log-rank; P <0.001).Conclusions Men who were treated with first-line docetaxel for mCRPC who had a low pretreatment NLR (≤3.0) had significantly longer OS. NLR may be a potentially useful clinical marker of systemic inflammatory response in predicting OS in men with mCRPC who receive docetaxel and may be helpful to stratify patients for clinical trials. These findings derived from a retrospective analysis need to be validated in larger populations in prospective studies, and in the context of different therapies.

KW - chemotherapy

KW - docetaxel

KW - metastatic castration-resistant prostate cancer

KW - neutrophil-to-lymphocyte ratio

KW - overall survival

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84920124479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920124479&partnerID=8YFLogxK

U2 - 10.1111/bju.12531

DO - 10.1111/bju.12531

M3 - Article

VL - 114

SP - E11-E17

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 6

ER -